BioCentury
ARTICLE | Company News

UCB buys rights to seizure candidate

April 20, 2018 7:52 PM UTC

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones.

The Belgian pharma plans to submit an NDA to FDA this year for the short-acting benzodiazepine derivative to treat acute repetitive seizures in epilepsy patients. ...